Related Experiment Video
Updated: May 20, 2026
07:10
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Tiotropium versus placebo for chronic obstructive pulmonary disease
Charlotta Karner1, Jimmy Chong, Phillippa Poole
1Population Health Sciences and Education, St George’s, University of London, London, UK. ckarner@sgul.ac.uk.
The Cochrane Database of Systematic Reviews
|July 13, 2012
Summary
Tiotropium improves quality of life and reduces exacerbations in COPD patients. However, mortality risk increased with the soft mist inhaler, warranting caution.
Area of Science:
- Pulmonary Medicine
- Pharmacology
Background:
- Tiotropium is a widely accepted once-daily maintenance therapy for stable chronic obstructive pulmonary disease (COPD).
- Recent trials, including those with soft mist inhalers, necessitate an updated efficacy review.
Purpose of the Study:
- To evaluate randomized controlled trials (RCTs) comparing tiotropium efficacy against placebo in COPD patients.
- Focus on clinically significant endpoints for COPD management.
Main Methods:
- Systematic search of Cochrane Airways Group's Specialised Register of Trials and ClinicalTrials.gov.
- Inclusion of parallel group RCTs of at least three months comparing tiotropium with placebo.
- Data extraction on study quality, outcomes, and adverse effects; analysis using RevMan 5.1.
Main Results:
- 22 good-quality RCTs with 23,309 COPD participants were included.
- Tiotropium significantly improved quality of life (SGRQ scores) and reduced exacerbations (OR 0.78) and hospitalizations due to exacerbations (OR 0.85).
- No significant difference in all-cause mortality or hospitalizations; however, the soft mist inhaler showed increased mortality risk compared to placebo.
Conclusions:
- Tiotropium improves quality of life and reduces exacerbations in COPD patients, with a NNTB of 16 for exacerbation prevention.
- While effective for exacerbation management, caution is advised with tiotropium delivered via soft mist inhaler due to increased mortality risk.
- Tiotropium remains a reasonable choice for stable COPD management, pending further trials on delivery devices.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...